Recombinant monoclonal antibodies: Versatile tools for research, diagnostics, and disease therapy

The development of hybridoma technology in 1975 by Köhler and Milstein enabled the creation and reproducible production of mouse monoclonal antibodies with defined specificities. This ushered in a new era of basic research, diagnostic, and therapeutic possibilities. During the almost 50 years that have followed those landmark experiments, monoclonal antibody technology has evolved to leverage the unique properties of the immune systems of different species and to incorporate other biotechnological advances, most notably recombinant DNA technology.

Compared to hybridoma-derived antibodies, recombinant monoclonal antibodies offer many advantages to both the antibody developer/manufacturer and the end user. This webinar will provide an overview of the antibody development technologies and the antibody formats currently available. The focus will be on how the properties of recombinant monoclonal antibodies compare to those of polyclonal and hybridoma-derived monoclonal antibodies and how these properties impact the applications in which they are used.

Key learning objectives

• How recombinant DNA technology has been applied to monoclonal antibody development
• How recombinant monoclonal antibodies compare to hybridoma-derived antibodies
• The antibody format options uniquely available through recombinant DNA technology

Who should attend?

• Scientists working with antibodies in research and development
• Professionals sourcing custom monoclonal antibodies as critical product components

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.